Many physiological perturbations can cause anemia. In cancer patients, activation of the immune system leads to the production of proinflammatory cytokines including tumor necrosis factor alpha (TNF), that have been shown to inhibit red-cell production via poorly understood mechanisms. Treatment of anemia by human recombinant erythropoietin (EPO) is strongly suspected to induce tumor growth.
Introduction
The majority of tumors are largely infiltrated by inflammatory cells, such as myelomonocytes and macrophages [1] . In response to the inflammatory environment, these cells produce inflammatory mediators including chemokines and cytokines. These mediators are tightly associated with cancer progression in combination with genetic alterations [2] . One of them, the Tumor Necrosis Factor alpha (TNF), is widely found in the inflammationassociated cancer microenvironment [3] [4] [5] [6] . Interestingly, because TNF is commonly present in cancer and inflammatory diseases, it has been implicated in cancer-and inflammationrelated anemia. Indeed, patients suffering from cancer and chronic inflammation are often anemic [7] . Moreover, in vitro and in vivo studies have led to the conclusion that TNF inhibits hematopoietic progenitors from undergoing erythroid differentiation [8] [9] [10] [11] [12] [13] [14] [15] . Anti-TNF treatment is effectively used for the treatment of chronic inflammatory diseases, but leads to increased risk of infection [16, 17] . Despite the beneficial effects of anti-TNF, this treatment may promote different types of cancers [18, 19] .
Several events may trigger anemia, including iron deficiency, hemolysis and hemorrhage. In non-hematopoietic cancer, anemia can also result from the activation of the immune system with the release of inflammatory cytokines that affect red-cell production in patients. So far, one well described effect of cytokine release is the reduction of erythropoietin synthesis by kidneys [20] . In this specific case, anemia is usually treated with human recombinant EPO (EPO). Nevertheless, this treatment addresses only the symptoms, not the cause of the anemia. Furthermore, EPO can provoke cardiovascular and thrombo-embolic side effects, as well as possible tumor progression [21] [22] [23] [24] . Indeed, cancer cells in many tumor types express the Erythropoietin receptor (EPOR) [25] , and the interaction between Erythropoietin and the EPOR can activate the expression of genes implicated in angiogenesis hematopoietic cells independently from Erythropoietin deficiency. We reported that TNF prevented the induction of erythroid differentiation in correlation with decreased expression of erythroid-specific genes and perturbations to the balance between GATA-1 and GATA-2 [13] [14] [15] .
In the present work, we studied the effect of TNF on the development of CD34 + HSPCs in the presence of EPO. In this model, different steps of erythropoiesis were successfully reproduced in vitro. We show that, in the heterogeneous cell population that constitutes the CD34 + HSPC culture, TNF acts on EPO-treated HSPCs by perturbing erythroid development. This effect was found to correlate with changes in the key transcription factors, GATA-1, GATA-2 and PU.1. Moreover the direct effect of TNF on erythroid progenitors has been confirmed by analyzing erythrospecific markers in isolated erythroid (GPA + ) cells.
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Cell culture and treatment
Human umbilical cord blood was obtained from the Clinique Bohler in Luxembourg.
For ethical reasons, cord blood cells were collected with written informed consent for use in research in agreement with the National Committee of Research Ethics in Luxembourg. The blood was collected in heparinized tubes. The mononucleated cell fraction was isolated using Ficoll TM (GE Healthcare, Roosendaal, The Netherlands) density gradient medium. CD34 + HSPCs or GPA + cells were selected using magnetic cell sorting. Purification was performed following the manufacturer's instructions (MACS Miltenyi, Utrecht, The Netherlands). The average purity of the cells obtained was around 96% of CD34 + cells.
After isolation, the cells were cultured in serum-free culture medium for cell expansion and erythroid differentiation (Stem Cell II, Sigma-Aldrich, Bornem, Belgium), to which a cytokine cocktail containing Interleukin 3 (IL3, Reliatech, Wolfenbüttel, Germany) and stem cell factor (SCF, Reliatech) was added. Interleukin 3 (10 ng/mL) was added together with SCF (10 ng/mL) for 3 days following CD34 + cell enrichment. Erythroid differentiation was achieved by adding 2 U/mL human recombinant erythropoietin (EPO) (Eprex, a kind gift of Janssen-Cilag) to the medium. EPO was added on day 0, whereas IL3 was removed on day 4
and SCF was removed on day 6. The medium was also supplemented with L-glutamine and penicillin/streptomycin (Lonza, Vervier, Belgium). The cells were maintained at 2 x 10 5 cells/mL. TNF (20 ng/mL; ReliaTech) was added 1 h before EPO (Figure S1A ).
K562 and TF1 cells were provided by DSMZ (Deutsche Sammlung für
Mikroorganismen und Zellkulturen; Braunschweig, Germany). These cells were cultured and treated as previously described [13, 15] . All cells were kept in 5% CO 2 at 37 °C. M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -7 -
Assays of cell proliferation, viability and morphology and erythroid differentiation
Cell number and viability were assessed using trypan blue dye exclusion. For evaluation of cell morphology, cytospin preparations were stained with May-Grünwald/Giemsa solution (Merck, Leuven, Belgium). Benzidine staining was used to detect the pseudoperoxidase activity of hemoglobin in cells. Images were collected with a Leica DM 2000 microscope.
Flow cytometry
HSPCs (2 x 10 5 ) were washed three times in PBS, before incubation with 5 µL of antibody for 90 min at 4 °C. FITC-labeled CD34 (clone 8G12) and CD41a (clone HIP8), PElabeled CD11b (clone D12), CD36 (clone CB38), and CD38 (clone HB7) and PE-Cy TM 5labeled GPA (235a; clone HIR2) antibodies were used (BD Biosciences, Erembodegem, Belgium). The corresponding isotype control antibodies (BD Biosciences) were used to set the gating levels. The samples were fixed with 2% formaldehyde after being washed twice with 1X PBS. Analysis was performed on a FACS Calibur flow cytometer (BD Biosciences).
The statistical analysis was based on 10,000 events per sample using FlowJo ® software (version 8.8.7, Tree Star, Ashland Oregon, USA).
Fluorescence microscopy
HSPCs (5 x 10 5 ) were washed three times in PBS. Cell pellets were then resuspended in 100 µL of 1X PBS containing 3 µL of GPA antibody (235a; clone HIR2; BD Biosciences) and incubated for 2 h at 4 °C. After washing three times with 1X PBS, cells were fixed with 2% formaldehyde and stained with Hoechst 33342 (1 µg/mL; Merck, Leuven, Belgium). Five microliters of stained cells were mounted on slides and observed with an Olympus CellM fluorescent microscope (Aartselaar, Belgium).
Western blotting
Up to 4 x 10 6 HSPCs were used to prepare nuclear, cytoplasmic and total protein M a n u s c r i p t extracts, as previously described [15] . Denatured proteins (10 µg or 20 µg) were separated on an SDS-PAGE gel. The proteins were transferred to a PVDF membrane that was then saturated for 1 h in 5% BSA or non-fat dry milk in PBS-Tween20 (PBS-T). The membranes were probed with antibodies against GATA-1 (C20X), GATA-2 (H-116), PU.1 (T-21), EPOR (M20), -globin, β-globin, -globin (Santa Cruz Biotechnology, Tebu Bio, Boechout, Belgium) and β actin (AC-15, Sigma-Aldrich). After washing with PBS-T, the membranes were incubated with peroxidase-conjugated antibodies (Santa Cruz Biotechnology). The proteins were then visualized using chemiluminescence detection (ECL, GE Healthcare) and
were revealed by autoradiography. Chemiluminescence was analyzed with the Kodak image station 440 CF (Kodak, Analis, Suarlée, Belgium) and quantified with the Kodak 1D image analysis software. The fold change of relative protein expression was normalized to the internal control, β actin.
Immunoprecipitation assays
Immunoprecipitation assays were performed using MACS protein G microbeads from MACS Miltenyi. Two hundred micrograms of nuclear and cytoplasmic proteins obtained from primary hematopoietic cells were incubated with 100 µL of protein G beads and 2 µg of GATA-1 (C20X) antibody (Santa Cruz Biotechnology). This mixture was mixed gently overnight at 4 °C. The immune complex was immobilized in a microMACS separation column and isolated according to the manufacturer's instructions. Immunoprecipitated proteins were loaded in an SDS-PAGE electrophoresis gel followed by western blot with GATA-1 (N1) and PU.1 (T-21) antibodies (Santa Cruz Biotechnology).
Electrophoretic mobility shift assay
Ten micrograms of nuclear extracts from TF1 or HSPCs was incubated for 30 min on ice with [ 32 P]ATP-labeled oligonucleotides in a reaction mixture containing protease inhibitors, 10 mM Tris-HCl, pH 8.5, 5% glycerol, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -9 -DTT, 1 mM MgCl 2 , 2.5 mM poly(dI-dC), 0.2 mg/mL BSA and 4 mg/mL spermidine. For supershift the nuclear extracts and labeled oligonucleotide probes were incubated with the reaction mixture for 30 min on ice prior to 30 min incubation with 2 µg p50 (H119X) and p65 (C20X) antibodies (Santa Cruz Biotechnology). The sequence of the NFB probe was: sense 5'-AGTTGAGGGACTTTCCCAGGC-3'. The corresponding binding site is underlined.
Annealing and labeling was performed as described previously [15] .
Real time PCR
RNA was extracted from 3 x 10 6 EPO-stimulated CD34 + cells treated with TNF or left untreated, using Trizol (Invitrogen, Merelbeke, Belgium) and cleaned using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). RNA quantity was measured by spectrophotometry (Nanodrop ® ND-1000).
The RT 2 PCR Array First Strand Kit (SuperArray, Tebu-Bio, Boechout, Belgium) was used to synthesize cDNA from 1.5 µg of RNA according to the manufacturer's instructions.
Real time PCR was performed using a customized RT 2 Profiler PCR Array System kit and the primers listed in Table S1 according to the manufacturer's instructions. The samples were analyzed in a 7300 Real Time PCR system (Applied Biosystems, Halle, Belgium). The results were calculated using the CT method and were normalized to the GAPDH housekeeping gene.
Transient transfection assays and plasmids
TF1 cells (3.75 x 10 6 ) were electroporated using the Gene Pulser (BioRad, Nazareth, Belgium). Each pulse was made at 250 V and 950 µF with 5 µg of DNA in a medium added to 0.1% SVF. The reporter plasmids under the control of GATA-1 is pGL3-GATA-Luc [47] whereas the Renilla-expressing pHRG-TK plasmid (Promega, Leiden, The Netherlands) was used as an internal control. The pXM-GATA1 expressing vector was used to express M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -10 -exogenous GATA-1 in TF1 cells [48] . Twenty-four hours after transfection, the cells were Orion microplate luminometer (Berthold). Firefly activity was normalized to Renilla and results were expressed as a ratio in arbitrary units.
Statistics
Data are expressed as mean ± S.D. and were analyzed by Student's t-test. Results were considered statistically significant when *P <0.05, **P <0.01 and ***P <0.001.
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Results

TNF affects EPO-mediated erythroid development of CD34 + cells
CD34 + HSPCs were isolated from umbilical cord blood to an average purity of approximately 96% (Figure 1) . Following CD34 + isolation, cell populations were characterized by analyzing specific hematopoietic markers with flow cytometry. As expected, results show a heterogeneous population with erythro-, myelo-, megakaryo-and lymphoblastic features (Figure 1) . The cell culture procedure used to study the effect of TNF on EPO-mediated erythropoiesis was designed as described in Figure S1A . The culture medium was supplemented with 20 ng/mL TNF on days 0, 4 and 6, 1 h before EPO stimulation. As shown in the control EMSA experiment, NF-Bp50/p65 was activated in TNF-treated cells, indicating that CD34 + cells are sensitive to TNF ( Figure S1B) .
Moreover, the percentage of CD34 + cells significantly decreased from day 4 to day 9 of treatment with EPO alone and EPO/TNF ( Figure S1C ). This suggests that cells underwent 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -12 -expression of GPA, another erythro-specific marker, was significantly decreased by 2.8-fold on day 9 of TNF treatment ( Figure 2C) . This down-regulation was also observed by fluorescent microscopy, as fluorescent intensity was lower in TNF-treated cells ( Figure S2) .
Similarly, flow cytometry showed a decrease in the percentage of GPA + cells after 4 and 9 days of TNF treatment ( Figure 2C) . Together, results showed that TNF reduced both the percentage of GPA + cells and the expression level of GPA in these cells. Moreover, megakaryocytic CD41a and myelo-monocytic CD11b, as well as neutrophil CD10, eosinophil CD15 and macrophage CD16 markers were not affected (data not shown). Furthermore, we observed that TNFα increased cell proliferation ( Figure 2D) . Altogether, our results provide evidence that TNF significantly prevents EPO-mediated erythroid differentiation of HSPCs in our culture system. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -13 -independent from the expression level of endogenous GATA-1 in these culture conditions because GATA-1 had low basal expression in TF1 cells (Figure 3B ). (Figure 4B) . These results suggest that TNF mediates its inhibiting effect by affecting transcription factors associated with GATA-1, rather than GATA-1's expression level.
TNF inhibits GATA-1 transactivation in TF1 cells
GATA
TNF affects the expression of
Effect of TNF on the interaction between GATA-1 and PU.1
PU.1 and GATA-1 are described as physically interacting with each other, which results in the inhibition of GATA-1 transactivation and, therefore, the down-regulation of erythroid specific genes [49] . To assess the possible capacity of TNF to affect GATA-1 activity via PU.1 over-expression, the interaction between GATA-1 and PU.1 was studied by immunoprecipitation assay in HSPCs that had undergone EPO-mediated differentiation in the presence or absence of TNF. The results show that PU.1 co-immunoprecipitated with M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 -14 -GATA-1 in the nuclear protein extracts from TNF-treated HSPCs after 4 days, whereas it did not in control cells ( Figure 4C ). This result suggests that PU.1 contributes to TNFmediated inhibition of erythropoiesis by directly interacting with GATA-1.
TNF down-regulates erythro-specific gene expression
To correlate the inhibiting effect of TNF on GATA-1 activity with GATA-1 target gene expression, we analyzed glycophorin A (GPA), EPOR and globin (,  and ) gene expression in EPO-and EPO/TNF-treated HSPCs at both the mRNA and protein levels. All the genes studied were found to be down-regulated in the presence of TNF in comparison to EPO-differentiated cells that were not treated with TNFα. Real-time PCR analysis showed a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -15 -To verify the direct effect of TNF on erythroid progenitors, HSPC were stimulated by EPO with or without TNF treatment. Cells were treated for 9 days based on the results of flow cytometry. This result showed a more important inhibitory effect of TNF on GPA expression level at day 9 compared to day 4 (Figure 2C, GPA, MFI=f (days of treatment) ).
TNF acts directly on erythroid cells
GPA + cells were isolated and Western blot analysis showed that GATA-1, GATA-2 and PU.1 expression remained over-expressed in TNF-treated cells. Moreover, globin expression remained lower in these cells compared to EPO-stimulated cells (Figure 6 ). This is in agreement with a delay of erythroid differentiation and correlates with the low expression of GPA as shown in figure 2C and S2. Results demonstrate that TNF inhibits erythroid development through a direct effect on early erythroid progenitors.
Discussion
We used CD34 + HSPCs purified from umbilical cord blood, which are commonly used At the molecular level, this study indicates the effect of TNF on the combination of transcription factors that leads to physiological hematopoietic lineage commitment [35] [36] [37] . In erythropoiesis, the GATA-1 and GATA-2 transcription factors have essential roles, and a quantitative balance in their protein levels is required to achieve erythroid lineage development [51] . GATA-2 plays a role in early progenitor cell proliferation, and activates GATA-1 gene expression, which, conversely, silences GATA-2 expression in erythroid progenitors [52] . GATA-1 deficiency leads to death due to severe anemia [38] , while GATA-2 deficiency leads to embryonic death [41] . Moreover, Ikonomi et al. reported that GATA-2 over-expression induced the arrest of erythroid differentiation in K562 cells [53] . However, it has also been reported that over-expression of GATA1 in erythroid cells, both in vitro, and in and inhibiting its binding to the DNA of erythro-specific genes [46, 49, 57] . We show in this study that TNF induced increased expression of the myeloid and lymphoid transcription factor, PU.1 [58, 59] . The analysis of GATA-1/PU.1 interaction by immunoprecipitation showed that the TNF-mediated increase in PU.1 expression was associated with the formation of the GATA-1/PU.1 complex in the nuclear extracts from EPO-induced HSPCs.
These results support a critical role for PU.1 in TNF-mediated inhibition of erythropoiesis, likely by affecting GATA-1 activity in HSPCs. In correlation with this proposal, TNFmediated inhibition of erythropoiesis was associated with the down-regulation of only GATA-1 target genes. Furthermore, persistent over-expression of GATA-2 is in accordance with the decreased activity of GATA-1, as GATA-2 has been reported to be up-regulated in the absence of GATA-1 [60] . However, over-expression of GATA-2 might contribute to progenitor renewal.
Altogether, our results indicate that TNF affects distinct regulatory steps that are implicated in erythroid maturation and differentiation. We show that TNF plays a critical role in the impairment of the balance between GATA-1 and GATA-2. Moreover, we provide, for the first time, the evidence that TNF induces PU.1 protein over-expression in HSPCs and perturbs the normal pattern of erythroid-implicated factors, thus promoting deregulation of lineage commitment despite the presence of EPO. Furthermore, the analysis of globin and transcription factor expression in GPA + erythroid cells after TNF treatment of HSPCs supported the hypothesis of a direct effect of TNF on erythroid progenitors.
Therefore, we suggest that cancer-related anemia results in part, from a direct interaction between HSPCs and pro-inflammatory cytokines released in the bone marrow and tumor microenvironment. According to our results this interaction triggers modifications in specific transcription factor networks implicated in the regulation of the different lineages commitment. While EPO is efficient for treating anemia associated with Erythropoietin M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -20 -M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -25 -M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -27 - 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 EPO-stimulated CD34 + cells were treated with TNF or left untreated for 4 days. Nuclear (nucl) and cytoplasmic (cyto) proteins were extracted and GATA-1 was immunoprecipitated using GATA-1 (C20X) antibody. GATA-1 (N1) and PU.1 (T-21) antibodies were then used to reveal GATA-1 and PU.1 by immunoblotting. One out of three independent experiments is shown. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -29 -EPOR in total protein extracts from CD34 + cells treated with TNF or left untreated for 2, 3 and 4 days. actin was used as an internal control. One out of three independent experiments is shown. 
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